Moderna
MRNA
784 hedge funds and large institutions have $22.3B invested in Moderna in 2026 Q2 according to their latest regulatory filings, with 148 funds opening new positions, 258 increasing their positions, 239 reducing their positions, and 83 closing their positions.
78% more first-time investments, than exits
New positions opened: 148 | Existing positions closed: 83
43% more capital invested
Capital invested by funds: $15.6B → $22.3B (+$6.67B)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
8% more funds holding
Funds holding: 726 → 784 (+58)
2.31% more ownership
Funds ownership: 78.01% → 80.31% (+2.3%)
8% more repeat investments, than reductions
Existing positions increased: 258 | Existing positions reduced: 239
4% less call options, than puts
Call options by funds: $1.75B | Put options by funds: $1.81B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$320M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$251M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$185M |
| 4 |
BAMCO Inc
New York
|
+$103M |
| 5 |
Morgan Stanley
New York
|
+$55.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$181M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$123M |
| 3 |
Goldman Sachs
New York
|
-$99.9M |
| 4 |
Two Sigma Investments
New York
|
-$97.9M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$92M |
MRNA Hedge Fund Activity: Q2 2026 in Review
784 of the 8,348 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q2 2026, worth a combined $22.3B — up 43% from $15.6B a quarter earlier.
Buyers outnumbered sellers: 148 funds opened new MRNA positions and 83 closed out — a net gain of 65 holders — while 258 added to existing stakes and 239 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $320M. The largest seller was Alyeska Investment Group, cutting an estimated $181M.
- 784 institutional investors held Moderna (MRNA) as of Q2 2026, up from 726 in Q1 2026.
- Funds reported $22.3B of Moderna stock for Q2 2026, up 43% quarter-over-quarter.
- 148 funds opened new Moderna positions in Q2 2026 and 83 closed out, a net change of +65 holders.
- The largest Moderna buyer in Q2 2026 was Fidelity Investments, an estimated $320M added.
- The largest Moderna seller in Q2 2026 was Alyeska Investment Group, an estimated $181M sold.
Based on aggregated 13F filings for Q2 2026.